AI Robotics in Medicine
PublicTracking updates in AI Robotics in the healthcare industry
NVIDIA's $10B Helix JV meets rising health AI oversight
Thursday, Jun 11, 2026
AI is moving from pilots to scaled, regulated deployment: NVIDIA’s $10B Helix JV and expanded SK alliance attack compute, memory, and power bottlenecks, while its exclusive Abridge deal pushes the stack into clinical workflows.
At the same time, public‑sector use and guardrails are ramping—HHS AI use cases surged (FDA up 148%) amid new federal directives, and the UK MHRA is launching an AI safety sandbox—yet many projects remain pre‑deployment and some growth reflects reporting changes.
Watch how capital‑intensive build‑outs intersect with tightening healthcare regulation to determine real‑world adoption and risk.
Tracking: Medicine Robotics · AI Medicine · AI Healthcare
Geography: United States, European Union, United Kingdom, Canada, Israel, China, Japan, South Korea, India, Singapore, Australia, United Arab Emirates, Saudi Arabia, San Francisco Bay Area, Boston/Cambridge (MA), Seattle, New York City, London, Cambridge (UK), Berlin, Munich, Toronto, Montreal, Tel Aviv, Shanghai, Beijing, Shenzhen, Tokyo, Seoul, Bengaluru, Singapore (city-state)
1. NVIDIA unveils $10B Helix JV, expands SK alliance, inks Abridge pact
NVIDIA launched Helix Digital Infrastructure, a $10 billion–backed joint venture with KKR and others to build AI data center and power infrastructure globally.
The company also expanded its alliance with SK Group around AI supercomputing, CPUs, and robotics, aligning with long-term memory supply and “AI factory” research.
Separately, NVIDIA entered an exclusive partnership with Abridge to develop healthcare-focused AI models for clinical use.
Simply Wall St frames these moves as embedding NVIDIA’s GPUs, CPUs, and software deeper in areas constrained by compute, memory, and power.
The initiatives broaden potential demand and push NVIDIA into regulated clinical workflows, while increasing exposure to capital-intensive projects and healthcare regulatory risk. NVIDIA shares recently traded around $200.
42, up 40. 5% over the past year.
Key facts:
- NVIDIA launched Helix Digital Infrastructure, a $10b-backed JV with KKR and others.
- Helix aims to build AI data center and power infrastructure globally.
- NVIDIA expanded its SK Group alliance on AI supercomputing, CPUs, and robotics.
- NVIDIA partnered exclusively with Abridge to develop healthcare AI models for clinical use.
- NVIDIA shares around $200.42, up 40.5% over the past year.
Why it matters: Helix targets the power and capacity bottlenecks that limit AI deployment, while the SK Group collaboration works to secure memory supply and advance “AI factory” capabilities.
The Abridge deal moves NVIDIA deeper into clinical workflows, where regulatory scrutiny and integration demands are high but healthcare impact and stickiness can be significant.
Together, these bets could diversify growth beyond hyperscalers—yet they also hinge on partner execution, heavy capital commitments, and regulators’ comfort with AI in sensitive sectors.
2. BPC: HHS AI use cases surge; FDA up 148% in FY 2025
AI use cases across HHS jumped sharply from FY 2024 to FY 2025, led by a 148% year-over-year increase at the FDA, according to a Bipartisan Policy Center analysis of HHS’s AI Use Cases Inventory.
The CDC rose 87%, CMS 78%, and NIH 51%; NIH remains the largest overall AI user, and CDC saw the greatest relative growth. Most use cases are still in pre-deployment, and some increases may reflect new reporting requirements rather than new deployments.
Generative AI and natural language processing are the most common tools. HHS rolled out ChatGPT to all employees in September 2025; CDC deployed an internal generative AI chatbot, and FDA expanded its internal AI tool, Elsa.
CMS outlined a 2026–2031 “AI first” framework to train thousands, while Trump administration actions—a January 2025 OMB-directed push, a late-March national AI policy framework, and a June 2 cybersecurity order—aim to guide and secure federal AI use, including protections for rural hospitals.
Key facts:
- FDA AI use cases rose 148% year-over-year in FY 2025.
- CDC increased 87%; CMS 78%; NIH 51% in FY 2025.
- NIH remains the largest overall AI user within HHS.
- Most AI use cases are still in pre-deployment stages.
- Generative AI and NLP are the most common tools used.
Why it matters: Rapid AI uptake inside HHS signals looming changes in how federal health agencies oversee, pay for, and operate healthcare—especially as many projects move from pre-deployment to production.
Expanded internal tools and workforce training suggest agencies will embed AI in day-to-day tasks ranging from analytics to staff support.
A national AI policy framework could reduce a patchwork of state rules, simplifying compliance for health AI vendors and providers.
The new cybersecurity order’s timelines and protections for rural hospitals underscore rising expectations that AI systems in healthcare be secured quickly and rigorously.
Watch how many pre-deployment projects go live, how agencies measure outcomes, and how governance addresses reporting versus true adoption.
3. MHRA launches AI sandbox to strengthen medicine safety evidence
The UK Medicines and Healthcare products Regulatory Agency (MHRA) is launching a regulatory sandbox to test AI tools with companies and researchers, establishing how they can improve the accuracy and safety assessment of medicines, better predict risks and side effects, and prove reliability.
In its first phase, the sandbox will evaluate a maximum of five AI-driven approaches, with operational parameters co-designed this summer with industry and academic partners.
The programme also aligns with efforts to reduce animal testing and follows the European Commission’s roadmap on phasing out animals in chemical safety, as well as January’s European Commission–US FDA joint guidance on AI in drug development.
UK Health Innovation Minister Preet Gill and MHRA Chief Executive Lawrence Tallon said the sandbox aims to generate stronger safety evidence and speed access to innovative treatments.
In parallel, industry voices are calling for substantial reform to the UK’s healthcare AI regulation, signaling demand for clearer, system‑wide rules to complement pilots like the sandbox.
Key facts:
- MHRA is launching an AI regulatory sandbox for medicine safety testing.
- First phase will test up to five AI-driven approaches.
- MHRA will set operational parameters this summer with industry and academia.
- UK Health Innovation Minister Preet Gill backed the sandbox to speed safer treatments.
- Industry has called for substantial reform to UK healthcare AI regulation.
Why it matters: A regulator-run sandbox can de-risk AI in drug development by generating credible evidence on safety and reliability, making it easier for innovators to invest and for patients to benefit sooner.
It also supports a shift away from animal testing by validating alternative, model-based methods. However, the initial scope—only five approaches—means near-term impact will be measured.
The parallel industry call for broader reform suggests the UK will need cohesive, system‑wide rules on healthcare AI.
Watch which projects enter the sandbox, how performance is evaluated, and how findings translate into formal guidance that shapes future approvals.